EGFR and non-small cell lung carcinoma: Current clinical decisions for advanced NSCLC in first-line treatment are based on the presence of genetic aberrations, such as sensitizing epidermal growth factor receptor (EGFR) mutations, and translocations of anaplastic lymphoma kinase (ALK).